Medicines

Fulltext search

For help on how to get the results you want, see our search tips.

Search results

Categories

Human (56) Apply Human filter

Medicine name

Active substance / international non-proprietary name (INN) / common name

Medicine

Referrals Remove Referrals filter Direct healthcare professional communication Remove Direct healthcare professional communication filter European public assessment reports (EPAR) (803) Apply European public assessment reports (EPAR) filter Summaries of opinion (29) Apply Summaries of opinion filter Withdrawn applications (84) Apply Withdrawn applications filter Paediatric investigation plans (221) Apply Paediatric investigation plans filter Orphan designations (257) Apply Orphan designations filter

Referral name

Referral status

European Commission final decision (16) Apply European Commission final decision filter Procedure started (1) Apply Procedure started filter

Referral safety status

Yes (8) Apply Yes filter

Referral type

Article 20 procedures (12) Apply Article 20 procedures filter Article 31 referrals (5) Apply Article 31 referrals filter

Referral reference number

Referral decision making model

PRAC-CAT-CHMP-EC (1) Apply PRAC-CAT-CHMP-EC filter PRAC-CHMP-EC (13) Apply PRAC-CHMP-EC filter

Referral authorisation model

Centrally and nationally authorised products (mixed) (5) Apply Centrally and nationally authorised products (mixed) filter Centrally authorised product(s) (12) Apply Centrally authorised product(s) filter

Referral PRAC recommendation

Risk minimisation measures (10) Apply Risk minimisation measures filter Suspension (2) Apply Suspension filter Variation (1) Apply Variation filter

Referral procedure start date

From:

To:

Referral PRAC recommendation date

From:

To:

Date of opinion

From:

To:

Decision date

From:

To:

ATC code

Medicine type

Additional monitoring Remove Additional monitoring filter Biosimilar Remove Biosimilar filter Generic Remove Generic filter Orphan medicine Remove Orphan medicine filter Accelerated assessment (3) Apply Accelerated assessment filter Conditional approval (13) Apply Conditional approval filter Exceptional circumstances (5) Apply Exceptional circumstances filter

Related medicine

Therapeutic area

Last updated

From:

To:

This week This month Last week Last month

First published

From:

To:

56 results

Remove all filtersRemove all filters

Medicine type Generic Remove Generic filter Biosimilar Remove Biosimilar filter Orphan medicine Remove Orphan medicine filter Additional monitoring Remove Additional monitoring filter

Medicine Referrals Remove Referrals filter Direct healthcare professional communication Remove Direct healthcare professional communication filter

Sort by

List item

Direct healthcare professional communication (DHPC): Vaxzevria (previously COVID-19 Vaccine AstraZeneca): risk of thrombocytopenia (including immune thrombocytopenia) with or without associated bleeding

Active substance: ChAdOx1-SARS-COV-2, DHPC type: Safety signal, Last updated: 13/10/2021
List item

Direct healthcare professional communication (DHPC): Polivy (polatuzumab vedotin) 140 mg powder for concentrate for solution for injection: Important information on plastic vial flip-off cap colour

Active substance: polatuzumab vedotin, DHPC type: Quality defect, Last updated: 04/05/2020
List item

Direct healthcare professional communication (DHPC): COVID-19 Vaccine Janssen: link between the vaccine and the occurrence of thrombosis in combination with thrombocytopenia

Active substance: adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein (Ad26.COV2-S), DHPC type: Safety signal, Last updated: 26/04/2021
List item

Direct healthcare professional communication (DHPC): COVID-19 Vaccine Janssen: Contraindication in individuals with previous capillary leak syndrome and update on thrombosis with thrombocytopenia syndrome

Active substance: adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein (Ad26.COV2-S), DHPC type: Safety signal, Last updated: 19/07/2021
List item

Direct healthcare professional communication (DHPC): COVID-19 Vaccine Janssen: Risk for immune thrombocytopenia (ITP) and venous thromboembolism (VTE)

Active substance: adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein (Ad26.COV2-S), DHPC type: Safety signal, Last updated: 13/10/2021
List item

Direct healthcare professional communication (DHPC): COVID-19 mRNA Vaccines Comirnaty and Spikevax: risk of myocarditis and pericarditis

Active substance: Single-stranded, 5’-capped messenger RNA produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2, CX-024414 (single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2), DHPC type: Safety signal, Last updated: 19/07/2021

56 results

Direct healthcare professional communication (DHPC): Vaxzevria (previously COVID-19 Vaccine AstraZeneca): risk of thrombocytopenia (including immune thrombocytopenia) with or without associated bleeding

Direct healthcare professional communication (DHPC): Polivy (polatuzumab vedotin) 140 mg powder for concentrate for solution for injection: Important information on plastic vial flip-off cap colour

Direct healthcare professional communication (DHPC): COVID-19 Vaccine Janssen: link between the vaccine and the occurrence of thrombosis in combination with thrombocytopenia

Direct healthcare professional communication (DHPC): COVID-19 Vaccine Janssen: Contraindication in individuals with previous capillary leak syndrome and update on thrombosis with thrombocytopenia syndrome

Direct healthcare professional communication (DHPC): COVID-19 Vaccine Janssen: Risk for immune thrombocytopenia (ITP) and venous thromboembolism (VTE)

Direct healthcare professional communication (DHPC): COVID-19 mRNA Vaccines Comirnaty and Spikevax: risk of myocarditis and pericarditis